

I. AMENDMENTS

In the claims:

Please add new claims 39 and 40 as follows.

After entry of the amendments, the pending claims will recite as follows.

20. (Amended 01/09/04) A pharmaceutical composition comprising the composition of Claim 27, and a pharmaceutically acceptable carrier or diluent.
23. (Amended 01/09/04) A method for mounting an immune response in an animal to Dengue virus infection, the method comprising administering to the animal the composition of Claim 27.
24. (Original) The method according to Claim 23, wherein the animal is a human.
27. (Previously Amended) A composition comprising a first and second component, wherein the first component is a vector comprising more than one DNA sequence selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 antigen, a DNA sequence encoding a Dengue virus serotype 2 antigen, a DNA sequence encoding a Dengue virus serotype 3 antigen, or a DNA sequence encoding a Dengue virus serotype 4 antigen and wherein the more than one DNA sequences are under the transcriptional control of a T7 RNA polymerase promoter and the second component is a recombinant Modified Vaccinia Ankara (MVA) virus comprising a DNA sequence encoding T7 RNA polymerase.
28. (Original) The composition of Claim 27, wherein the vector of the first component is a plasmid.
32. (Original) A cell containing the composition of Claim 27.
39. (New) The composition according to Claim 27, wherein the DNA sequence encoding Dengue virus antigen is selected from the group consisting of DNA sequences encoding preM, E and NS1 antigens.

40. (New) The composition according to Claim 27, wherein the DNA sequence encoding the T7 RNA polymerase is inserted at a site of a naturally occurring deletion with the MVA genome.